Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)Christine E. Ryan, Reid W. Merryman, David C. Fisher et al.|Blood|2024Cited by 0
Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximabHari S. Raman, Reid W. Merryman, Robert Redd et al.|Blood|2025Cited by 0
Could treatment modification based on early response assessment improve results in DLBCL?Hari S. Raman, Jennifer L. Crombie|Hematology|2025Cited by 0